We conducted a pilot study to assess the effect of atorvastatin on HIV replication. Patients with stable HAART-controlled infection interrupted therapy and were randomly assigned to a control group or to start atorvastatin 40 or 80 mg/day. Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4.
aLluita contra la SIDA
cInternal Medicine Department, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
Received 7 October, 2005
Accepted 19 October, 2005
Sponsorship: This work was partly supported by the Spanish Fondo de Investigación Sanitaria (FIS), project 02/0879 and Red Temática Cooperativa de Investigacion en SIDA (RIS). J. Blanco is a researcher from Fundació de Recerca Germans Trias i Pujol.